| 22.5 1.6 (7.66%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 27.77 | 1-year : | 32.44 |
| Resists | First : | 23.78 | Second : | 27.77 |
| Pivot price | 19.19 |
|||
| Supports | First : | 19.71 | Second : | 17.2 |
| MAs | MA(5) : | 20.84 |
MA(20) : | 19.57 |
| MA(100) : | 19.35 |
MA(250) : | 12.58 |
|
| MACD | MACD : | 0.1 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 91.8 |
D(3) : | 81.4 |
| RSI | RSI(14): 60.2 |
|||
| 52-week | High : | 31 | Low : | 2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PTN ] has closed Bollinger Bands are 28.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 22.53 - 22.61 | 22.61 - 22.69 |
| Low: | 20.43 - 20.53 | 20.53 - 20.62 |
| Close: | 22.31 - 22.49 | 22.49 - 22.65 |
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
Thu, 16 Apr 2026
Q1 2026 Palatin Technologies Inc Earnings Call Transcript - GuruFocus
Sun, 12 Apr 2026
Palatin Technologies, Inc. (PTN) - Minichart
Thu, 19 Feb 2026
Palatin Technologies’ Rare-Obesity Strategy Sets Up a Catalyst-Rich 2026 for Its MC4R Pipeline (NYSE: PTN) - The Globe and Mail
Tue, 17 Feb 2026
PTN | Palatin Technologies, Inc. Analyst Forecasts - Quiver Quantitative
Tue, 17 Feb 2026
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update - PR Newswire
Tue, 17 Feb 2026
PALATIN TECHNOLOGIES INC SEC 10-Q Report - TradingView — Track All Markets
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|